Key result
Stage 3-5 chronic kidney disease was associated with significantly higher serum soluble thrombomodulin levels compared to healthy controls (p < 0.001), correlating with disease severity.
Why the study?
Are serum levels of soluble thrombomodulin elevated in patients with stage 3-5 chronic kidney disease compared to healthy controls?
Population
67 patients with stage 3-5 chronic kidney disease (CKD) and 19 healthy volunteers (total n=86).
Design
Cross-sectional
Authors
Loading...
Serum soluble TM associates with CKD severity; leaves open its utility as a biomarker pending prospective validation.
Observational (n=86)
Are serum levels of soluble thrombomodulin elevated in patients with stage 3-5 chronic kidney disease compared to healthy controls?
p-value: p=<0.001
Serum soluble thrombomodulin is significantly elevated in patients with stage 3-5 CKD and correlates strongly with disease severity and renal function.
Bao et al. (2014) conducted an observational in stage 3-5 chronic kidney disease (n=86). Stage 3-5 chronic kidney disease vs. Healthy controls was evaluated on Serum levels of soluble thrombomodulin (TM) (p=<0.001). Stage 3-5 chronic kidney disease was associated with significantly higher serum soluble thrombomodulin levels compared to healthy controls (p < 0.001), correlating with disease severity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: